Abstracts tagged "Osteoarthritis"

Abstract Number: 1980 • 2019 ACR/ARP Annual Meeting
Disorganization of Chondrocyte Columns in the Growth Plate During Experimental Osteoarthritis in Mice
Ana Lamuedra¹, Víctor Luis Ruiz-Perez ², Paula Gratal ¹, Raquel Largo ³ and Gabriel Herrero-Beaumont ³, ¹IIS - Fundacion Jimenez Diaz, Madrid, Madrid, Spain, ²Instituto de Investigaciones Biomédicas 'Alberto Sols', Madrid, Madrid, Spain, ³IIS-Fundación Jiménez Díaz, Madrid, Madrid, Spain
Background/Purpose: Osteoarthritis (OA) is a biomechanical joint disease mainly affecting articular cartilage and subchondral bone. A great variety of animal models, especially mice, are used…
Abstract Number: 2179 • 2019 ACR/ARP Annual Meeting
Erosive Hand Osteoarthritis, Metabolic Syndrome and Knee Osteoarthritis: A Cross-sectional Study Using Data from the PROCOAC Cohort
Natividad Oreiro¹, Ignacio Rego-Pérez ¹, Maria T. Silva ¹, Sara Relaño ¹, Mercedes Fernandez-Moreno ², Paula Ramos-Louro ¹, Alejandro Duran-Sotuela ¹, Sonia Pertega ³ and Francisco J. Blanco ¹, ¹Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ²Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España. CIBER-BBM, A Coruña, Spain, ³Unidad de Epidemiología Clínica y Bioestadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain
Background/Purpose: Erosive hand osteoarthritis (EOA) is often considered a more severe form of hand OA. However, more data are needed regarding this phenotype to conclude…
Abstract Number: 2220 • 2019 ACR/ARP Annual Meeting
Abaloparatide Followed by Alendronate on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis
Nancy Lane¹, Richard Weiss ², Bruce Mitlak ³, Yamei Wang ⁴, Guillermo Valenzuela ⁵ and Chad Deal ⁶, ¹University of California at Davis Medical Center, Sacramento, CA, ²Radius Health, Inc, Waltham, ³Radius Health, Inc, Waltham, MA, ⁴Radius Health, Inc, Waltham, ⁵Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁶Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Osteoporosis (OP) and osteoarthritis (OA) are often comorbid conditions in the elderly, with prevalence of OP in patients with OA reported as high as…
Abstract Number: 875 • 2019 ACR/ARP Annual Meeting
Effect of the Dr. Bart Application on Healthcare Use and Clinical Outcomes in People with Osteoarthritis of the Knee And/or Hip in the Netherlands; A Randomized Controlled Trial
Tim Pelle¹, Karen Bevers ¹, Job van der Palen ², Frank van den Hoogen ³ and Cornelia van den Ende ¹, ¹Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, ²Department of research methodology, Univeristy of Twente, Enschede, Netherlands, ³Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Self-management is of paramount importance in non-surgical treatment of knee/hip osteoarthritis (OA). Modern technologies offer the possibility to support self-management 24/7. We developed an…
Abstract Number: 1308 • 2019 ACR/ARP Annual Meeting
Subject Enrichment Criteria for Phase 3 Studies of Lorecivivint (SM04690), a Potential Disease-Modifying Knee Osteoarthritis Drug: A Post Hoc Study on the Effects of Baseline Comorbid Pain and Joint Space Width on Patient-Reported Outcomes
Sarah Kennedy ¹, Chris Swearingen ¹, Jeyanesh Tambiah¹, Daniel Clauw ² and Philip G Conaghan ³, ¹Samumed, LLC, San Diego, ²Division of Rheumatology, Department of Internal Medicine and Division of Anesthesia, Michigan Medicine, Ann Arbor, MI, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: Patient-reported outcomes (PROs) in knee osteoarthritis (OA) trials have been difficult to accurately measure due to heterogenous sources of pain (e.g., from comorbid conditions…
Abstract Number: 1327 • 2019 ACR/ARP Annual Meeting
The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial
Yusuf Yazici¹, Sarah Kennedy ², Chris Swearingen ² and Jeyanesh Tambiah ², ¹Samumed, LLC, San Diego, CA, ²Samumed, LLC, San Diego
Background/Purpose: Lorecivivint (LOR, SM04690) is a small-molecule, intra-articular (IA) CLK/DYRK1A inhibitor which modulates the Wnt pathway and has demonstrated beneficial effects on patient-reported outcomes (PROs)…
Abstract Number: 1982 • 2019 ACR/ARP Annual Meeting
Senescent Synoviocytes in Knee Osteoarthritis Correlate with Disease Biomarkers, Synovitis, and Knee Pain
Christopher Yohn ¹, Robert O'Brien ¹, Stephanie Lussier ¹, Casey Berridge ¹, Rathi Ryan ¹, Ali Guermazi ², Mahru An ¹, Remi-Martin Laberge ¹, Benjamin Hsu¹, Carl Millward ¹, Kate Doherty ¹ and Jamie Dananberg ¹, ¹Unity Biotechnology, Brisbane, CA, ²Boston Medical Center, Boston
Background/Purpose: Background/Purpose: Cellular senescence is a natural state in which a cell permanently halts division through upregulation of a set of intracellular proteins including p16INK4A…
Abstract Number: 2181 • 2019 ACR/ARP Annual Meeting
Natural Disease Progression in Hand Osteoarthritis: Results from a Belgian Ten-years Prospective Cohort Study
Lisa Pardaens ¹, Tine Vanhaverbeke ¹, Jordy Vandercruyssen ¹ and Ruth Wittoek², ¹Ghent University, Gent, Belgium, ²Ghent University Hospital, Gent University, Gent, Belgium
Background/Purpose: Limited evidence is available about natural disease progression in hand osteoarthritis (HOA). A previous study of the Ghent HOA cohort showed a positive association…
Abstract Number: 2244 • 2019 ACR/ARP Annual Meeting
What Are the Prescribing Trends and Satisfaction Levels with Analgesics for Osteoarthritis as Reported by US Rheumatogists, Orthopaedic Surgeons, and Primary Care Physicians?
Thomas Schnitzer¹, Rebecca Robinson ², Lars Viktrup ², Joseph Cappelleri ³, Andrew Bushmakin ³, Leslie Tive ⁴, Jennifer Mellor ⁵, Nathan Williams ⁵, Pavlina Hubanova ⁵ and James Jackson ⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Eli Lilly and Company, Indianapolis, IN, ³Pfizer Inc, Groton, CT, ⁴Pfizer, Inc, New york, NY, ⁵Adelphi Real World, Bollington, England, United Kingdom
Background/Purpose: To describe patterns of care and physician satisfaction with prescribed treatments for osteoarthritis (OA).Methods: Data were collected from February-May 2017 using US Adelphi Disease…
Abstract Number: 886 • 2019 ACR/ARP Annual Meeting
Mesenchymal Stem Cell Senescence Alleviates Their Chondrogenic and Seno-Suppressive Properties, Contributing to Osteoarthritis Development
Olivier Malaise¹, Yassin Tachikart ², Michael Constantinides ², Marcus Mumme ³, Daniele Noel ², Jing Wang ⁴, Christian Jorgensen ² and Jean-Marc brondello ², ¹GIGA Research, CHU and University of Liège, Liège, Belgium, ²IRMB, INSERM U1183, University of Montpellier, Montpellier, France, ³University Hospital of Basel, Basel, Switzerland, ⁴INM, INSERM U1050, University of Montpellier, Montpeller, France
Background/Purpose: Tissue accumulation of p16INK4A-positive senescent cells is associated with age-related disorders such as osteoarthritis (OA). These senescent cells induce a tissue loss of function through…
Abstract Number: 1309 • 2019 ACR/ARP Annual Meeting
Concordance of Baseline Pain Measures (Across Two Reporting Instruments) Influences Treatment Effect: Post Hoc Analysis of a Phase 3 Randomized Controlled Trial of Triamcinolone Acetonide Extended-Release in Patients with Knee Osteoarthritis
Philip G Conaghan¹, Edgar Ross ², Alan Kivitz ³, Dennis Turk ⁴, Andrew Spitzer ⁵, Deryk Jones ⁶, Ryan Lanier ⁷, Amy Cinar ⁸, Joelle Lufkin ⁸ and Scott Kelley ⁸, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ²Brigham and Women's Hospital, Boston, MA, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴University of Washington, Seattle, ⁵Cedars-Sinai Medical Center, Los Angeles, ⁶Ochsner Sports Medicine Institute, Harahan, GA, ⁷Analgesic Solutions, Natick, ⁸Flexion Therapeutics, Burlington
Background/Purpose: In a Phase 3 randomized controlled study, differing efficacy results were observed when triamcinolone acetonide extended-release (TA-ER) was compared to conventional TA crystalline suspension…
Abstract Number: 1759 • 2019 ACR/ARP Annual Meeting
Methotrexate in Patients with Hand Erosive Osteoarthritis Refractory to Usual Treatments: A Randomized, Double-blind, Placebo-controlled Trial
stéphanie Ferrero ¹, Ruth Wittoek ², Edem Allado ³, Coralie Cruzel ⁴, Véronique Breuil ¹, Liana Euller Ziegler ⁵, Damien louille ⁶, Christian Roux⁷ and Joel Kremer ⁸, ¹University of Nice, nice, France, ²Ghent University Hospital, Gent University, Gent, Belgium, ³Centre Hospitalier Universitaire de Nancy, Nancy, France, ⁴Université Cote d'Azur, nice, France, ⁵PUPH CHU NICE, nice, France, ⁶Université Cote d'Azur, Nancy, France, ⁷Université Cote d'Azur, Nice, ⁸Albany Medical College, Albany, NY
Background/Purpose: No studies have assessed the effect of methotrexate (MTX) in osteoarthritis of the hand (HOA). The purpose of our study was to examine the…
Abstract Number: 1983 • 2019 ACR/ARP Annual Meeting
Preclinical Evaluation of Targeting TGF-beta Signaling and Senescence in ex Vivo Models of Human Knee and Spine Osteoarthritis
Jeroen Geurts¹, Cordula Netzer ², Stefan Schären ² and Thomas Hugle ³, ¹University Hospital Lausanne (CHUV), Lausanne, Switzerland, ²University Hospital Basel, Basel, Switzerland, ³University Hospital Lausanne, Lausanne, Switzerland
Background/Purpose: The absence of effective disease-modifying drugs remains an important unmet need in the treatment of osteoarthritis. In recent years, novel pharmacological treatments including targeting…
Abstract Number: 2183 • 2019 ACR/ARP Annual Meeting
Relation of Intra-Articular Knee Mineralization on CT to Knee Pain in People with or at Risk of Knee Osteoarthritis
Tuhina Neogi¹, John Lynch ², Mohamed Jarraya ³, David Felson ⁴, Na Wang ¹, Michael Nevitt ², James Torner ⁵, Beth Lewis ⁶ and Ali Guermazi ¹, ¹Boston University School of Medicine, Boston, MA, ²University of California at San Francisco, San Francisco, CA, ³Mercy Catholic Medical Center, Darby, ⁴Boston University School of Medicine, Department of Rheumatology, Boston, ⁵University of Iowa at Iowa City, Iowa City, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Intra-articular (i.a.) calcium crystal deposition is common in knee osteoarthritis (OA), particularly in end-stage disease. It is possible that low-grade inflammation related to crystals…
Abstract Number: 2409 • 2019 ACR/ARP Annual Meeting
24-hour Activity Profiling in People Living with Arthritis: Habits Matter
Lynne Feehan¹, Linda Li ¹, Na Lu ² and Hui Xie ³, ¹Arthritis Research Canada and University of British Columbia, Vancouver, Canada, Vancouver, BC, Canada, ²Arthritis Research Canada, Vancouver, Canada, Vancouver, BC, Canada, ³Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada
Background/Purpose: Current practices promoting change in physical activity classify individuals as being more or less active. However, across 24-hours people spend time in different types…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].